IRVINE, CA / ACCESSWIRE / June 16, 2017 / Khang & Khang LLP (the "Firm") announces a securities class action lawsuit against TherapeuticsMD, Inc. ("TherapeuticsMD" or the "Company") (NYSE MKT: TXMD). Investors who purchased or otherwise acquired shares between July 7, 2016 and April 9, 2017, inclusive (the "Class Period"), are encouraged to contact the Firm before June 19, 2017, the lead plaintiff motion deadline.
If you purchased TherapeuticsMD shares during the Class Period, please contact Joon M. Khang, Esq., of Khang & Khang LLP, 18101 Von Karman Avenue, 3rd Floor, Irvine, CA 92612, by telephone: (949) 419-3834, or by e-mail at [email protected].
There has been no class certification in this case yet. Until certification occurs, you are not represented by an attorney. You may also choose to take no action and remain a passive class member.
According to the Complaint, during the Class Period, TherapeuticsMD made false and/or misleading statements and/or failed to disclose that its New Drug Application ("NDA") submission for TX-004HR was deficient and was not supported by the complete TX-004HR clinical program, which would likely cause a delay of the U.S. Food and Drug Administration's ("FDA") potential approval of the NDA. On April 10, 2017, the Company issued a press release announcing that the FDA identified deficiencies in its NDA for TX-004HR. When this news was announced, TherapeuticsMD's stock price fell materially, which harmed investors according to the Complaint.
If you wish to learn more about this lawsuit, or if you have any questions about this notice or your rights, please contact Joon M. Khang, Esq., a prominent litigator for almost two decades, by telephone: (949) 419-3834, or via e-mail at [email protected].
This press release may constitute Attorney Advertising in certain jurisdictions.
Contact
Joon M. Khang, Esq.
Telephone: 949-419-3834
Facsimile: 949-225-4474
[email protected]
SOURCE: Khang & Khang LLP